^
    Back
    Association details:
    Biomarker:BRINP3 mutation
    Cancer:Non Small Cell Lung Cancer
    Drug:Tagrisso (osimertinib) (EGFR inhibitor)
    Direction:Resistant
    Evidence:
    Evidence Level:
    Resistant: C3 – Early Trials
    Source:
    ASCO 2023
    Title:

    First report of ELUCIDATOR study: A prospective observational multicenter study on resistance mechanisms in patients with early disease progression during osimertinib.

    Published date:
    05/25/2023
    Excerpt:
    Germline mutations in BRCA1/2, TP53 and BRINP3 may confer early and unprecedented resistance to Osi monotherapy.
    DOI:
    10.1200/JCO.2023.41.16_suppl.3032